Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 219

1.

Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study.

Selewski DT, Ambruzs JM, Appel GB, Bomback AS, Matar RB, Cai Y, Cattran DC, Chishti AS, D'Agati VD, D'Alessandri-Silva CJ, Gbadegesin RA, Hogan JJ, Iragorri S, Jennette JC, Julian BA, Khalid M, Lafayette RA, Liapis H, Lugani F, Mansfield SA, Mason S, Nachman PH, Nast CC, Nester CM, Noone DG, Novak J, O'Shaughnessy MM, Reich HN, Rheault MN, Rizk DV, Saha MK, Sanghani NS, Sperati CJ, Sreedharan R, Srivastava T, Swiatecka-Urban A, Twombley K, Vasylyeva TL, Weaver DJ, Yin H, Zee J, Falk RJ, Gharavi AG, Gillespie BW, Gipson DS, Greenbaum LA, Holzman LB, Kretzler M, Robinson BM, Smoyer WE, Flessner M, Guay-Woodford LM, Kiryluk K; CureGN Consortium.

Kidney Int Rep. 2018 Aug 3;3(6):1373-1384. doi: 10.1016/j.ekir.2018.07.021. eCollection 2018 Nov.

2.

Aberrant Glycosylation of the IgA1 Molecule in IgA Nephropathy.

Novak J, Barratt J, Julian BA, Renfrow MB.

Semin Nephrol. 2018 Sep;38(5):461-476. doi: 10.1016/j.semnephrol.2018.05.016. Review.

PMID:
30177018
3.

Assay for galactose-deficient IgA1 enables mechanistic studies with primary cells from IgA nephropathy patients.

Reily C, Rizk DV, Julian BA, Novak J.

Biotechniques. 2018 Aug;65(2):71-77. doi: 10.2144/btn-2018-0042.

4.

Genome-wide association studies suggest that APOL1-environment interactions more likely trigger kidney disease in African Americans with nondiabetic nephropathy than strong APOL1-second gene interactions.

Langefeld CD, Comeau ME, Ng MCY, Guan M, Dimitrov L, Mudgal P, Spainhour MH, Julian BA, Edberg JC, Croker JA, Divers J, Hicks PJ, Bowden DW, Chan GC, Ma L, Palmer ND, Kimberly RP, Freedman BI.

Kidney Int. 2018 Sep;94(3):599-607. doi: 10.1016/j.kint.2018.03.017. Epub 2018 Jun 7.

PMID:
29885931
5.

Secondary IgA nephropathy.

Saha MK, Julian BA, Novak J, Rizk DV.

Kidney Int. 2018 Oct;94(4):674-681. doi: 10.1016/j.kint.2018.02.030. Epub 2018 May 24. Review.

PMID:
29804660
6.

Population Health, Ethnicity, and Rate of Living Donor Kidney Transplantation.

Reed RD, Sawinski D, Shelton BA, MacLennan PA, Hanaway M, Kumar V, Long D, Gaston RS, Kilgore ML, Julian BA, Lewis CE, Locke JE.

Transplantation. 2018 Dec;102(12):2080-2087. doi: 10.1097/TP.0000000000002286.

PMID:
29787519
7.

Redefining the Influence of Ethnicity on Simultaneous Kidney and Pancreas Transplantation Outcomes: A 15-Year Single-Center Experience.

Young CJ, MacLennan PA, Mannon EC, Reed RD, Shelton BA, Hanaway MJ, Agarwal G, Gaston RS, Julian BA, Kew CE 2nd, Kumar V, Mannon RB, Mehta S, Ong SC, Towns GC, Deierhoi MH, Locke JE.

Ann Surg. 2018 May 17. doi: 10.1097/SLA.0000000000002816. [Epub ahead of print]

PMID:
29781845
8.

Evaluation of Potential Living Kidney Donors in the APOL1 Era.

Freedman BI, Julian BA.

J Am Soc Nephrol. 2018 Apr;29(4):1079-1081. doi: 10.1681/ASN.2018020137. Epub 2018 Mar 9. No abstract available.

PMID:
29523593
9.

Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy.

Hastings MC, Bursac Z, Julian BA, Villa Baca E, Featherston J, Woodford SY, Bailey L, Wyatt RJ.

Kidney Int Rep. 2017 Aug 24;3(1):99-104. doi: 10.1016/j.ekir.2017.08.008. eCollection 2018 Jan.

10.

Serial Galactose-Deficient IgA1 Levels in Children with IgA Nephropathy and Healthy Controls.

Sanders JT, Hastings MC, Moldoveanu Z, Novak J, Julian BA, Bursac Z, Wyatt RJ.

Int J Nephrol. 2017;2017:8210641. doi: 10.1155/2017/8210641. Epub 2017 Nov 26.

11.

Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy.

Placzek WJ, Yanagawa H, Makita Y, Renfrow MB, Julian BA, Rizk DV, Suzuki Y, Novak J, Suzuki H.

PLoS One. 2018 Jan 11;13(1):e0190967. doi: 10.1371/journal.pone.0190967. eCollection 2018.

12.

Inhibition of STAT3 Signaling Reduces IgA1 Autoantigen Production in IgA Nephropathy.

Yamada K, Huang ZQ, Raska M, Reily C, Anderson JC, Suzuki H, Ueda H, Moldoveanu Z, Kiryluk K, Suzuki Y, Wyatt RJ, Tomino Y, Gharavi AG, Weinmann A, Julian BA, Willey CD, Novak J.

Kidney Int Rep. 2017 Jul 19;2(6):1194-1207. doi: 10.1016/j.ekir.2017.07.002. eCollection 2017 Nov.

13.

Apolipoprotein L1 Gene Effects on Kidney Transplantation.

Freedman BI, Locke JE, Reeves-Daniel AM, Julian BA.

Semin Nephrol. 2017 Nov;37(6):530-537. doi: 10.1016/j.semnephrol.2017.07.006. Review.

14.

Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.

Yanik MV, Irvin MR, Beasley TM, Jacobson PA, Julian BA, Limdi NA.

Pharmacotherapy. 2017 Nov;37(11):1366-1373. doi: 10.1002/phar.2032. Epub 2017 Nov 2.

15.

Prognostic Value of Serum Biomarkers of Autoimmunity for Recurrence of IgA Nephropathy after Kidney Transplantation.

Berthoux F, Suzuki H, Mohey H, Maillard N, Mariat C, Novak J, Julian BA.

J Am Soc Nephrol. 2017 Jun;28(6):1943-1950. doi: 10.1681/ASN.2016060670. Epub 2017 Mar 2.

16.

GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway.

Kiryluk K, Li Y, Moldoveanu Z, Suzuki H, Reily C, Hou P, Xie J, Mladkova N, Prakash S, Fischman C, Shapiro S, LeDesma RA, Bradbury D, Ionita-Laza I, Eitner F, Rauen T, Maillard N, Berthoux F, Floege J, Chen N, Zhang H, Scolari F, Wyatt RJ, Julian BA, Gharavi AG, Novak J.

PLoS Genet. 2017 Feb 10;13(2):e1006609. doi: 10.1371/journal.pgen.1006609. eCollection 2017 Feb.

17.

Apolipoprotein L1 and Chronic Kidney Disease Risk in Young Potential Living Kidney Donors.

Locke JE, Sawinski D, Reed RD, Shelton B, MacLennan PA, Kumar V, Mehta S, Mannon RB, Gaston R, Julian BA, Carr JJ, Terry JG, Kilgore M, Massie AB, Segev DL, Lewis CE.

Ann Surg. 2018 Jun;267(6):1161-1168. doi: 10.1097/SLA.0000000000002174.

PMID:
28187045
18.

Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis.

Siwy J, Z├╝rbig P, Argiles A, Beige J, Haubitz M, Jankowski J, Julian BA, Linde PG, Marx D, Mischak H, Mullen W, Novak J, Ortiz A, Persson F, Pontillo C, Rossing P, Rupprecht H, Schanstra JP, Vlahou A, Vanholder R.

Nephrol Dial Transplant. 2017 Dec 1;32(12):2079-2089. doi: 10.1093/ndt/gfw337.

19.

Effect of Replacing Race With Apolipoprotein L1 Genotype in Calculation of Kidney Donor Risk Index.

Julian BA, Gaston RS, Brown WM, Reeves-Daniel AM, Israni AK, Schladt DP, Pastan SO, Mohan S, Freedman BI, Divers J.

Am J Transplant. 2017 Jun;17(6):1540-1548. doi: 10.1111/ajt.14113. Epub 2017 Jan 3.

20.

A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.

Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, Sethi S, Tumlin JA, Mehta K, Hogan M, Erickson S, Julian BA, Leung N, Enders FT, Brown R, Knoppova B, Hall S, Fervenza FC.

J Am Soc Nephrol. 2017 Apr;28(4):1306-1313. doi: 10.1681/ASN.2016060640. Epub 2016 Nov 7.

Supplemental Content

Loading ...
Support Center